Page 20 - Aurobindo Pharma

Aurobindo eyes Teva's products in Europe

The company would reportedly finance the deal with a loan of more than $1 billion

Aurobindo eyes Teva's product sale in Europe

According to Bloomberg, Aurobindo will finance acquisition of 'overlapping drugs' with a loan of $1 billion

Aurobindo Pharma keeps up pace

Product approvals, Natrol drive US growth; European turnaround adds to performance

Aurobindo Pharma to step up product launches in US

The move is crucial to its ambitious goal of seeing $3 billion revenues by FY18

Aurobindo Q4 net up 39% at Rs 563 cr

Company crosses $2 billion revenue mark in FY16

Aurobindo Pharma gains on good Q4 results

The stock was up 5% at Rs 795 on the BSE.

Aurobindo Pharma Q4 profit jumps 40%; shares rise 4%

Net profit for the January-March quarter rose to Rs 5.63 billion from Rs 4.03 billion a year earlier

Aurobindo receives approval for pain relief drug

The product has an estimated market size of $50 mn for 12 months to March 2016, according to IMS Health data

Aurobindo Pharma gets USFDA nod for anaesthetic injection

The approved ANDA is generic version of Hospira Inc's Marcaine injection

Aurobindo Pharma gets USFDA nod for generic migraine drug

With this approval, the company has now a total of 260 abbreviated new drug application (ANDA) approvals from the USFDA

Aurobindo Pharma hits three-month high

The stock moved higher by 5% to Rs 809, its highest level since February 2, this year on the BSE.

Aurobindo gets US nod for seizures treatment drug

The company is eligible for 180 days of generic drug shared exclusivity

Aurobindo Pharma gets USFDA nod for two drugs

Heartburn relief medicine Famotidine tablets is expected to be launched in the second quarter of 2016-17

Aurobindo Pharma gains on USFDA nod for hypertension drug

The USFDA has approved manufacture and market Amlodipine and Valsartan tablets USP

Aurobindo Pharma gains on USFDA nod for gastroesophageal reflux drug

The USFDA nod is for Esomeprazole Magnesium delayed-release capsules USP in dosages of 20mg and 40mg.

Aurobindo Pharma gets USFDA nod for gastro reflux drug

The drug major said that the launch of the product is based on the settlement terms with AstraZeneca.

Aurobindo gets USFDA final nod for generic Nexium

The approved drug has an estimated market size of $4.2 billion for twelve months ending February, 2016

Aurobindo gets US FDA nod for gastrointestinal drug

This product is expected to be launched in the first quarter of FY17

Aurobindo Pharma gets final USFDA nod for gastro reflux drug

The firm said this product is expected to be launched in the first quarter of next fiscal

Aurobindo Pharma gets USFDA nod for antibiotic drug

The company will launch its antibiotic drug Vancomycin Hydrochloride in the later part of FY16-17